Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab
2024-517757-27-00Phase 4Completed
- Sponsor
- CSL Behring
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 4, open-label, single-arm trial of garadacimab in hereditary angioedema (HAE), sponsored by CSL Behring. Primary endpoints: Number of Participants with Treatment Emergent Adverse Events (TEAEs), Percentage of Participants with TEAEs and 3 more. Started Aug 2025; status: completed.
02
Drugs
garadacimab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2024-517757-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517757-27-00.